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Abstract
Background: Spectrum effects refer to the phenomenon that test performance varies across subgroups of a
population. When spectrum effects occur during diagnostic testing for cancer, difficult patient misdiagnoses can
occur. Our objective was to evaluate the effect of test indication, age, gender, race, and smoking status on the
performance characteristics of two commonly used diagnostic tests for bladder cancer, urine cytology and
fluorescence in situ hybridization (FISH).
Methods: We assessed all subjects who underwent cystoscopy, cytology, and FISH at our institution from 2003 to
2012. The standard diagnostic test performance metrics were calculated using marginal models to account for
clustered/repeated measures within subjects. We calculated test performance for the overall cohort by test
indication as well as by key patient variables: age, gender, race, and smoking status.
Results: A total of 4023 cystoscopy-cytology pairs and 1696 FISH-cystoscopy pairs were included in the analysis. In
both FISH and cytology, increasing age, male gender, and history of smoking were associated with increased
sensitivity and decreased specificity. FISH performance was most impacted by age, with an increase in sensitivity
from 17 % at age 40 to 49 % at age 80. The same was true of cytology, with an increase in sensitivity from 50 % at
age 40 to 67 % at age 80. Sensitivity of FISH was higher for a previous diagnosis of bladder cancer (46 %) than for
hematuria (26 %). Test indication had no impact on the performance of cytology and race had no significant
impact on the performance of either test.
Conclusions: The diagnostic performance of urine cytology and FISH vary significantly according to the patient
demographic in which they were tested. Hence, the reporting of spectrum effects in diagnostic tests should
become part of standard practice. Patient-related factors must contextualize the clinicians’ interpretation of test
results and their decision-making.
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Background
Bladder cancer (BC) represents 4.5 % of all new cancers
in the US with over 74,000 cases and it remains the 5th
most common in 2015 [1]. Typically, it presents with
hematuria, and 70 % of patients with BC initially have
non-muscle invasive bladder cancer (NMIBC). NMIBC
has a high chance of recurrence (60–85 %) and requires
long term surveillance [2]. Several guidelines exist for
the management of non-muscle invasive bladder cancer,
and include cystoscopy and urine-based tests for initial
screening and recurrence surveillance [3–5].
Cystoscopy is the community gold standard for the de-
tection of bladder tumors, and identifies nearly all papil-
lary and sessile tumors [6]. However, it is invasive and a
source of distress for patients. It also has a limited ability
to detect occult microscopic disease or the presence of
tumors in atypical locations. Microscopic disease is of
particular importance in BC because of prevalent field
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effect [7]. While urethral cancer is a rare event, [8]
upper tract tumors (UTUC) account for 5–10 % of
urothelial cell carcinoma and may lead to increased mor-
bidity and mortality if missed [9]. Therefore, guidelines
recommend adjunctive tests for detection of BC [3–5].
The two most common urine-based tests are voided
urine cytology and UroVysion™ (Vysis, Downers Grove,
IL) fluorescence in situ hybridization (FISH) assay. Most
physicians and their patients will assume that a positive
urine test indicates the presence of a tumor, and will
aggressively pursue a diagnosis.
The majority of physicians believe that a urine test will
perform similarly in all patient populations, but this may
be a false assumption. Test performance often varies
across patient subgroups and is termed spectrum effects
[10–12]. Although reporting spectrum effects for a given
test is endorsed by the STARD initiative, it is uncommon
in practice [13]. We are the first to evaluate for the
existence of spectrum effects in cytology and FISH
among patients being screened because of hematuria or
undergoing surveillance of NMIBC. Our hypothesis is
that test performance varies according to patient charac-
teristics. We analyzed the diagnostic performance by test
indication as well as four clinically significant demo-
graphic variables - age, gender, race, and smoking status.
The objective of this study was to determine the pres-
ence and magnitude of spectrum effects occurring in
cytology and FISH of a large contemporary cohort
undergoing bladder cancer screening.
Methods
Subject selection
After approval by the Duke University Health System
Institutional Review Board, all subjects who underwent
cystoscopy and cytology and/or UroVysion FISH at
Duke University Medical Center (DUMC) between 1/
2003 to 1/2012 for either hematuria evaluation or sur-
veillance of bladder cancer were identified. As the data
for the study was obtained through retrospective chart
review, a waiver of informed consent was approved by
the IRB. For patients with signs or symptoms of urinary
tract infection, the standard practice at our institution
was to collect a urine specimen for culture, treat the
patient with culture-specific antibiotics, and delay cyst-
oscopy and urine marker testing for 2–4 weeks to avoid
confounding the results.
Cystoscopy as the diagnostic gold standard for bladder
tumor
White light cystoscopy, the community gold standard in
diagnosis of bladder tumors, was used to determine the
presence or absence of a bladder tumor [4, 14–16].
Cystoscopy was chosen over biopsy as the standard
against which urine tests were compared because a
biopsy is obtained only in subjects with an abnormal
cystoscopy or urine test, which would subject the results
to considerable verification bias [17]. Cystoscopy results
were classified as positive, suspicious, or negative. A
positive cystoscopy serves as a surrogate for histo-
pathology, as nearly all visible tumors are malignant [6].
We required that cystoscopy occur within +/− 30 days
of the urine-based test to serve as the gold standard.
Cytology
Urine samples received in the Cytology Preparatory
Laboratory were prepared as ThinPrep slides (Cytyc
Corporation, Marlborough, MA). After samples were
centrifuged at 2800 rpm for 5 min, the supernatant was
removed to produce a cell pellet. Cell pellets were
washed with Cytolyt Solution. Two to three drops of
each patient sample was transferred into PreservCyt
Solution and fixed for 15 min. ThinPrep slides were then
produced by loading the samples into the ThinPrep 2000
Processor. The ThinPrep slides were stained with
Papanicolaou stain, cover-slipped and then screened by a
cytotechnologist before being evaluated by a cytopathol-
ogist. More than one cytopathologist was involved in the
analysis of the urine specimens during the study interval.
After cytological evaluation, the specimens were classi-
fied into one of four categories: negative, atypical, suspi-
cious for malignancy, or positive for malignancy.
UroVysion FISH test
Patient samples for UroVysion FISH were prepared
according to manufacturer recommendations (Abbott
Molecular Inc., Abbot Park, IL). The UroVysion Probe
mixture contains chromosome enumeration probes
(CEPs) labeled with Spectrum Red for visualization of
chromosome 3, Spectrum Green for visualization of
chromosome 7 and Spectrum Aqua for visualization of
chromosome 17, as well as a locus specific probe for
9p21 labeled with Spectrum Gold. The slides were coun-
terstained with DAPI and visualized with a fluorescence
microscope equipped with the appropriate filters for
signal enumeration of each fluorophore. A minimum of
25 morphologically abnormal cells per test were analyzed.
The UroVysion FISH result was defined as meeting one or
more of the following criteria: (i) ≥ 4 cells with gains of 2
or more chromosomes 3, 7, and 17 in the same cell, (ii) ≥
10 cells with tetrasomy of chromosomes 3, 7, and 17,
(iii) ≥ 10 cells showing gains of a single chromosome 3, 7,
or 17, and (iv) ≥ 12 cells with homozygous loss of 9p21
locus [18].
Statistical methods
Diagnostic test performance metrics and 95 % confi-
dence intervals (95 % CI) were calculated using logistic
models: (a) a generalized estimating equation (GEE)
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using an exchangeable (compound symmetry) covariance
structure, [19] and (b) a generalized linear mixed model
(GLMM) [19]. While both models take into account
clustered/correlated test results that occur due to re-
peated testing within subjects, they are different tech-
niques and results are interpreted differently [20]. The
GEE is a marginal model that is interpreted as “popula-
tion-averaged,” whereas the GLMM is a conditional
model interpreted in a “subject-specific” manner [21].
Sensitivity and specificity were calculated for the overall
cohort as well as by indication, age, gender, race, and
smoking status subgroups. Age was analyzed as a con-
tinuous variable, but the results are presented in age
decades for ease of interpretation. Indication, gender,
race, and smoking status were analyzed as categorical
variables. Smokers were stratified as “Never smokers,”
“Former smokers,” or “Current smokers,” as indicated in
their electronic medical charts. Smoking status was
available on all patients in both the cytology and FISH
cohorts. A two-sided p-value of 0.05 was used to define
statistical significance. Statistical analyses were con-
ducted using R 3.1.3 with packages lme4, geepack, and
BSagri installed.
Results
A total of 4023 pairs of cystoscopies and cytologies were
obtained from 871 unique subjects for the cytology ana-
lysis, and 1696 pairs of UroVysion tests and cystoscopies
from 827 unique subjects for the UroVysion FISH ana-
lysis. Baseline demographic characteristics of the study
cohort are shown in Table 1. In patients who had posi-
tive pathology in the cytology cohort, the AJCC stage
distribution was: 355 (81 %) stage 0, 33 (7.5 %) stage 1,
33 (7.5 %) stage 2, and 19 (4 %) stage 3. The grade distri-
bution was 199 (45 %) low grade and 239 (55 %) high
grade. In the FISH cohort, of patients who had positive
pathology, the AJCC stage distribution was: 183 (77 %)
stage 0, 24 (10 %) stage 1, 18 (8 %) stage 2, 12 (5 %)
stage 3, and 1 (<1 %) stage 4. The grade breakdown was
102 (43 %) low grade and 134 (56 %) high grade.
The diagnostic performance of urine cytology is shown
in Table 2 and Fig. 1. Increasing age was associated with
an increase in sensitivity and decrease in specificity of
urine cytology. Sensitivity increased by 17 %, from 50 %
in subjects ≤40 years to 67 % in those ≥80 years. In con-
trast, specificity declined from 53 % in subjects ≤40 years
of age to 36 % in subjects ≥80 years of age. Gender had
the greatest impact on cytology performance. Subject-
specific estimates of sensitivity derived from the GLMM
model were dramatically higher in men than women
(67 % vs 51 %), though specificity was lower (36 % vs
53 %). In subjects with a history of smoking, cytology
was 10 % more sensitive and proportionally less specific
compared with subjects who had never smoked. Race
and indication did not significantly impact cytology test
performance in either of the models.
The diagnostic performance of UroVysion FISH is
shown in Table 3 and Fig. 2. Again, increasing subject
age was associated with increased sensitivity and de-
creased specificity. Subject-specific estimates of test sensi-
tivity obtained from the GLMM model nearly tripled from
17 % in subjects ≤40 years of age to 49 % in those ≥80 years
of age. Contrarily, specificity decreased from 93 % in sub-
jects ≤40 years of age to 74 % in those ≥80 years of age.
The UroVysion FISH test was substantially less sensitive
Table 1 Clinical characteristics of the study population
Cytology cohort UroVysion FISH cohort
Sample size
Unique subjects 871 827
Test-cystoscopy pairs 4023 1696
Age (years, median) 66 (IQR: 56–75) 67 (IQR: 56–76)
< 40 34 (4 %) 29 (4 %)
40–50 89 (10 %) 84 (10 %)
50–60 162 (19 %) 152 (18 %)
60–70 248 (29 %) 227 (27 %)
70–80 222 (26 %) 217 (26 %)
≥ 80 113 (13 %) 118 (14 %)
Gender
Male 540 (62 %) 488 (59 %)
Female 328 (38 %) 339 (41 %)
Race
White 668 (78 %) 648 (78 %)
Black 157 (18 %) 154 (19 %)
Other 26 (3 %) 25 (3 %)
Smoking status
Current smoker 75 (9 %) 82 (10 %)
Former smoker 403 (48 %) 407 (49 %)
Never smoker 356 (43 %) 338 (41 %)
Indication for test
Hematuria 415 (48 %) 368 (44 %)
Urothelial carcinoma 331 (38 %) 322 (39 %)
Other 125 (14 %) 137 (17 %)
Cystoscopy result
Negative 2783 (69 %) 1324 (78 %)
Positive 752 (19 %) 185 (11 %)
Atypical/Suspicious 492 (12 %) 187 (11 %)
Urine test result
Negative 1632 (41 %) 1210 (71 %)
Positive 375 (9 %) 486 (29 %)
Atypical/Suspicious 2016 (50 %) -
IQR interquartile range
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in women than in men (28 % vs. 44 %), though its speci-
ficity was higher (88 % vs 78 %). Test performance was
similar in current and former smokers regardless of the
analysis model. However, in nonsmokers, test sensitivity
was approximately 15 % lower and specificity approxi-
mately 10 % higher than current and former smokers.
Race was not statistically significant in the correlative
models. Analysis of test performance by indication
revealed significant differences. FISH was dramatically
more sensitive for cancer surveillance (46 %) than for
hematuria (26 %). However, it was also less specific
(76 % vs 88 %).
There were 4,729 total cytologies collected, although
706 did not have a corresponding cystoscopy to perform
the above analysis. During the study period, 1898 (40 %)
were negative, 423 (9 %) positive, and 2408 (51 %) suspi-
cious or atypical. When suspicious/atypical cytology
results using the GLMM model were classified as
positive, the sensitivity was 62 % [95 % CI: 58–66 %] and
the specificity was 41 % [95 % CI: 38–44 %]. When these
Table 2 Diagnostic performance of urine cytology by patient subgroup
Risk factor Subgroup Method Sensitivity Specificity P-value
Estimate (%) LCI UCI Estimate (%) LCI UCI
Overall None GLMM 62 58 66 41 38 44 0.13
GEE 59 56 63 43 40 45 0.23
Age 40 GLMM 50 42 58 53 46 60 <0.001
50 55 49 60 48 44 53
60 59 54 63 44 41 47
70 63 59 67 40 37 43
80 67 62 71 36 32 40
40 GEE 50 43 57 52 46 58 0.006
50 53 48 59 49 45 53
60 57 53 61 45 42 48
70 60 57 64 42 39 44
80 64 60 68 38 35 42
Smoking Never GLMM 56 51 62 47 42 52 0.003
Former 66 62 71 37 33 41
Current 59 50 68 44 35 53
Never GEE 55 50 60 47 43 51 0.005
Former 63 59 67 39 36 43
Current 57 49 65 45 38 52
Gender Female GLMM 51 45 57 53 48 58 <0.001
Male 67 63 71 36 32 39
Female GEE 50 45 55 52 48 56 <0.001
Male 64 60 67 38 35 41
Race White GLMM 63 59 67 40 37 44 0.34
Black 61 53 68 43 36 50
Other 51 34 68 52 36 68
White GEE 60 56 64 42 39 45 0.25
Black 58 51 65 44 38 50
Other 49 35 63 53 39 67
Indication Hematuria GLMM 63 58 69 40 35 45 0.047
Cancer 63 59 68 40 36 44
Other 53 44 62 51 43 59
Hematuria GEE 61 56 65 42 38 46 0.059
Cancer 60 56 64 42 39 45
Other 52 45 59 51 44 57
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results were re-classified as negative, this had the effect of a
large increase in specificity 100 % [95 % CI: 100-100 %] with
a consequent decrease in sensitivity 0 % [95 % CI: 0-2 %].
For all the above analyses, suspicious cystoscopies were
considered positive since they will generally result in inter-
vention (e.g., bladder biopsy). To determine whether the
classification of suspicious cystoscopies dramatically af-
fected our results, we repeated the analyses with suspi-
cious cystoscopies classified as negative and found no
significant difference in our results, demonstrating that
the performance of cytology and UroVysion FISH are not
sensitive to how suspicious cystoscopies are classified.
This stands in contrast to the large effect seen in cytology
with a similar re-analysis that was mentioned above.
Discussion
Spectrum effects were first described by Mulherin et al.
as inherent variations in diagnostic test performance
among different subgroup populations [12]. We have
shown that urine-based tests for bladder cancer (a) have
poor diagnostic performance and (b) vary substantially
in accuracy in different patient populations. However,
the recognition of spectrum effects allows for a strategy
that should result in a clinically important gain for the
patient.
We stratified our cohort into four clinically relevant
subgroups and found that age, male gender, and a history
of smoking were all associated with increased sensitivity
in both cytology and UroVysion. Smoking and aging are
associated with altered cellular biology which might
lead to changes detectable by cytology or UroVysion
[22]. Epidemiologically, age and cigarette smoking have
also been associated with more advanced disease at
initial presentation [22, 23]. It is possible that the
improvement in sensitivity of cytology and UroVysion
is due to more advanced disease at presentation in these
Fig. 1 Cytology test performance characteristics by patient subgroups
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demographics. Horstmann et al. found that age was as-
sociated with higher false positive rates in cytology and
the NMP22 assay, which would translate to decreased
specificity and is consistent with our results [24]. The
analysis by indication also revealed increased sensitivity
for UroVysion but not cytology when used for cancer
surveillance compared to hematuria. This may also be a
reflection of advanced disease in that population. Inter-
estingly, Dimashkieh et al. found that both UroVysion
and cytology are slightly more sensitive in the context
of cancer surveillance than in hematuria [25].
Disease severity fails to explain why both tests were
more sensitive in males than females. While the inci-
dence of bladder cancer is three to four times higher in
men, women tend to present with more advanced
disease [26, 27]. An alternative explanation for the
gender disparity we observed is that gender-specific
genetic differences are affecting test performance. Recent
Table 3 Diagnostic performance of UroVysion FISH by patient subgroup
Risk factor Subgroup Method Sensitivity Specificity P-value
Estimate (%) LCI UCI Estimate (%) LCI UCI
Overall None GLMM 39 31 46 82 79 85 <0.001
GEE 38 32 45 77 75 80 <0.001
Age 40 GLMM 17 11 26 93 89 96 <0.001
50 23 16 31 90 86 93
60 31 24 39 86 83 89
70 40 33 47 81 77 84
80 49 41 57 74 68 79
40 GEE 20 14 28 89 85 92 <0.001
50 25 19 33 86 82 89
60 32 26 39 81 78 84
70 39 33 46 76 73 79
80 47 40 54 70 65 74
Smoking Never GLMM 25 18 34 89 86 92 <0.001
Former 46 38 54 77 72 81
Current 41 28 55 80 71 87
Never GEE 26 34 85 85 81 88 <0.001
Former 44 52 72 72 68 75
Current 40 51 76 76 68 82
Gender Female GLMM 28 20 36 88 84 92 <0.001
Male 44 36 52 78 74 82
Female GEE 28 22 36 84 80 87 <0.001
Male 43 37 37 73 69 77
Race White GLMM 40 33 47 81 77 85 0.219
Black 31 21 42 87 81 91
Other 37 17 61 83 65 93
White GEE 39 33 46 76 73 79 0.160
Black 31 23 41 82 76 87
Other 35 17 58 80 61 91
Indication Hematuria GLMM 26 19 35 88 84 92 <0.001
Cancer 46 38 54 76 71 80
Other 28 19 40 87 80 92
Hematuria GEE 29 22 37 83 79 86 <0.001
Cancer 44 38 52 71 67 75
Other 31 22 41 82 75 87
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studies have found gender differences at a cellular level,
and postulate that cells have a “sex” [28]. Shen et al. have
elucidated gender differences in bladder cancer biology
thought to be related to differential expression of sex
steroid receptors on urothelial cells [29]. Specifically, the
beta subunit of the estrogen receptor is the predominant
receptor expressed in the majority of bladder cancers,
and a positive correlation exists between degree of
estrogen receptor expression and tumor grade and stage
[29]. These gender differences in cancer biology may
result in differences in cytologic morphology. Distinct
patterns of chromosomal abnormalities between the
genders have been described in other cancers and it
is possible that the specific chromosomal aberrations
detected by the UroVysion test result in improved
sensitivity in men [30].
Proper stratification into relevant subgroups allows for
recognition of important spectrum associations [31].
There is value in discerning between low grade and high
grade lesions; high grade should be detected as early as
possible, while the likelihood of missing such a tumor
should be as low as possible. In high risk populations,
sensitivity is more important than specificity because the
consequences of a missed malignancy are great. FISH
exhibits such properties in the smoking subgroup,
whereas cytology does not have similar characteristics in
the same population. Therefore, a clinician should give
stronger consideration to FISH results than cytology re-
sults in smokers. Analogous spectrum effects can be
seen for indication and cytology.
There are other patient populations were the risks of a
procedure often outweigh the benefit. It is preferable for
a urine test with a high specificity and low sensitivity in
low grade disease to reduce the number of unnecessary
invasive procedures. Age and cytology illustrate this ef-
fect because as the patient age increases, so does the
specificity, with a reciprocal decrease in sensitivity. This
should spare the elderly patient avoidable cystoscopies.
Fig. 2 UroVysion FISH test performance characteristics by patient subgroups
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The tradeoff would be that some tumors may be missed
for a period of time, but the literature surrounding active
surveillance suggest this is safe [32].
Limitations
Our study was retrospective, and longitudinal in nature
leaving us unable to control for significant variables,
such as the EORTC risk scores, that predict the prob-
ability of recurrence and progression of bladder cancer.
With 19 % of cystoscopies in the cytology cohort classi-
fied as positive, this cohort was at higher risk for bladder
cancer than the average US population. Additionally,
while the sensitivity could have been improved with nar-
row band imaging or fluorescent cystoscopy, these tech-
nologies were not available at our institution for the
entirety of the study period. For the purposes of our
analyses, suspicious lesions on cystoscopy were classified
as positive. When we correlated this classification with
pathology, only 59 % of pathology specimens were found
to have cancer, reflecting a limitation of this classifica-
tion. However, when we performed a sensitivity analysis
with suspicious cystoscopies classified as negative, our
results were not significantly different, indicating a
minimal impact of this limitation on the interpretation
of the results. The data were collected over a 10 year
time frame; so indications for using the tests have chan-
ged over time as have technique of verification of test
results. Furthermore, more than one cytopathologist was
involved over the period examined and literature sug-
gests high inter-observer discrepancy, but this reflects
the real world. Urine cytology has a low sensitivity and
is highly operator-dependent in the setting of low grade
disease [33]. In experienced hands, however, specificity
is about 90 % [34]. Indeed, our own data supports this
conclusion, and shows an increasing percentage of reported
atypical/suspicious cytologies over time (Fig. 3).
Conclusions
We are the first to show that urine-based bladder cancer
tests display spectrum effects. The reporting of spectrum
effects in diagnostic tests should become part of standard
practice. Knowledge of these effects allows the physician
to properly interpret the results and has a meaningful
impact on a patient’s clinical care.
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